325 related articles for article (PubMed ID: 26464261)
1. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Clin Drug Investig; 2015 Dec; 35(12):795-805. PubMed ID: 26464261
[TBL] [Abstract][Full Text] [Related]
2. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
3. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
BMC Urol; 2013 Oct; 13():51. PubMed ID: 24144225
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.
Arlandis-Guzman S; Errando-Smet C; Trocio J; Arumi D; Rejas J
BMC Urol; 2011 May; 11():9. PubMed ID: 21599928
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
6. Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Actas Urol Esp; 2016 Mar; 40(2):96-101. PubMed ID: 26556482
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
Angulo JC; Valpas A; Rejas J; Linden K; Kvasz M; Snedecor SJ
Clin Drug Investig; 2014 May; 34(5):297-307. PubMed ID: 24567280
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
12. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Hart WM; Abrams P; Munro V; Retsa P; Nazir J
J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
[TBL] [Abstract][Full Text] [Related]
16. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
17. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
20. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
Hsiao SM; Liao SC; Chen CH; Chang TC; Lin HH
Maturitas; 2014 Dec; 79(4):428-34. PubMed ID: 25238744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]